Ionis Completes Enrollment in Key Phase 3 Angelman Syndrome Trial
Event summary
- Ionis has fully enrolled the pivotal cohort (136 pediatric patients) in its Phase 3 REVEAL study for obudanersen, an investigational treatment for Angelman syndrome.
- Topline data from the study is expected in the second half of 2027.
- The adult cohort (Cohort 2) enrollment is projected to complete by Q3 2026.
- Obudanersen has received Orphan Drug, Fast Track, and Rare Pediatric designations from the FDA.
The big picture
Ionis' completion of enrollment in the REVEAL study marks a critical step in developing a potential first-ever treatment for Angelman syndrome, a rare neurodevelopmental disorder with no approved therapies. The study's design reflects the diverse genetic profiles of AS patients, positioning obudanersen as a potentially broad-spectrum solution. Ionis' expertise in RNA-targeted therapies, demonstrated by its success with SPINRAZA and QALSODY, underscores its leadership in addressing complex neurological conditions.
What we're watching
- Regulatory Pathway
- Whether the Fast Track and Rare Pediatric designations will accelerate obudanersen's approval process.
- Clinical Efficacy
- The impact of the Bayley-4 assessment results on obudanersen's potential as a disease-modifying treatment.
- Market Opportunity
- The pace at which Ionis can expand obudanersen's application to other Angelman syndrome genotypes through the CHAMPION study.